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Abstract: We studied a protein phosphorylation system 
that is regulated by the dopamine-mimetic ergot bromo- 
criptine. Bromocriptine was found to inhibit selectively 
the endogenous phosphorylation of a threonine residue(s) 
in 50,000- and 60,000-dalton proteins in a synaptosome 
fraction. The bromocriptine-sensitive phosphorylation is 
stimulated by calcium and by calmodulin, and occurs pre- 
dominantly in the brain. The inhibitory effect of bromo- 
criptine was not mimicked by 3,4-dihydroxyphenylethyl- 
amine or by any of the neurotransmitters and related 
agents tested, but was mimicked, although less effec- 
tively, by other ergots that contain peptide moieties. In 
the hippocampus, the brain region with the highest con- 
tent of the 50,000- and 60,000-dalton proteins, the ergo- 
peptine-sensitive protein phosphorylation appears to be 
localized to interneurons or cell bodies whose axons syn- 
apse outside the hippocampus. The results raise the pos- 
sibility that some of the bromocriptine- and ergopeptine- 
induced pharmacological effects in the CNS may be 
mediated by the inhibition of the calcium/calmodulin-de- 
pendent phosphorylation of these specific proteins. Key 
Words: Bromocriptine - Calcium - Calmodulin- Ibo- 
tenate-Protein phosphorylation. Stratford C. A. et al. 
Ergopeptine-sensitive calcium-dependent protein phos- 
phorylation system in the brain. J .  Neurochern. 42, 842- 
855 (1984). 
Protein phosphorylation is involved in the regu- 
lation of enzymatic and cellular activities in a va- 
riety of biological systems, including the nervous 
system, where it has been proposed to serve as a 
mediator of at least some of the physiological ef- 
fects of calcium (see Krebs and Beavo, 1979; Glass 
and Krebs, 1980; Greengard, 1981; Cohen, 1982, for 
reviews). A number of calcium-dependent protein 
phosphorylation systems in brain tissue have been 
described (DeLorenzo, 1976; Schulman and Green- 
gard, 1978; Takai et al., 1979; Wrenn et al., 1980); 
however, a direct relationship between calcium-de- 
pendent phosphorylation and neuronal function has 
yet to be established. In the present study, we in- 
vestigated interactions between neuroactive agents 
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and calcium-dependent phosphorylation in a syn- 
aptosome fraction of rat brain. We report here that 
the 3 ,Cdihydroxyphenylethylamine (dopamine)-mi- 
metic ergot bromocriptine (2-Br-a-ergocriptine) and 
other peptide-containing ergots selectively inhibit 
the calmodulin-stimulated phosphorylation of 
50,000- and 60,000-dalton proteins which are highly 
enriched in the brain. Lesion studies on the guinea 
pig hippocampus are also presented, and indicate 
that these phosphoproteins are predominantly lo- 
calized to interneurons or cell bodies whose axons 
synapse outside the hippocampus. 
These bromocriptine-sensitive phosphoproteins 
have electrophoretic mobilities in sodium dodecyl 
sulfate (SDS) similar to those of diphenylhydan- 
~ ~ 
Abbreviations used: BrC-,,, BrC-P,o, Bromocriptine-sensi- 
tive phosphoproteins with molecular weights of 50,000 and 
60,000, respectively; ChAT, Choline acetyltransferase; Dopa- 
mine, 3,4-Dihydroxyphenylethylamine; DPH, Diphenylhydan- 
tom; DPH-L, DPH-M, Diphenylhydantoin-sensitive proteins; 
GABA, y-Aminobutyric acid; GAD, Glutamate decarboxylase; 
KRB, Krebs-Ringer bicarbonate buffer; SDS, Sodium dodecyl 
sulfate; Serotonin, 5-Hydroxytryptamine. 
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toin (DPH)-sensitive phosphoproteins termed DPH- 
L and DPH-M (DeLorenzo, 1976), the major Ca2+/ 
calmodulin-dependent phosphoproteins in a syn- 
aptosomal membrane fraction (Schulman and 
Greengard, 1978), and the 51,000- and 62,000-dalton 
phosphoproteins in the postsynaptic density frac- 
tion (Grab et al., 1981). DPH-L and DPH-M have 
been shown to be present in synaptic vesicle, syn- 
aptic junctional complex, postsynaptic density, and 
synaptic membrane fractions (DeLorenzo, 1980). 
DeLorenzo and coworkers (DeLorenzo et al., 1979; 
DeLorenzo, 1980) have provided evidence that 
Ca2+/calmodulin-dependent phosphorylation of 
DPH-L and DPH-M is correlated with depolariza- 
tion-dependent calcium uptake and neurotrans- 
mitter release. The bromocriptine-sensitive phos- 
phorylation system is discussed in relation to the 
above Ca2 + /calmodulin-dependent phosphopro- 
teins as well as with respect to a possible associa- 
tion with a particular neurotransmitter system. 
MATERIALS AND METHODS 
Materials 
Male Sprague-Dawley rats (126- 150 g) were obtained 
from Charles River. Male guinea pigs (350-400 g) were 
obtained from Buckberg Animals (Tomkins Cove, NY). 
[Y-~~P]ATP (>SO00 Ci/mmol), [ l-14C]~-glutamic acid ( S O  
Ci/mmol), and [ 14C]acetyl-coenzyme A (56.6 Ci/mmol) 
were purchased from Amersham. Acrylamide, 
N,N,N',N'-tetramethylene ethylenediamine, and X-ray 
film (XAR-5) were from Eastman Kodak. N,N'-Methy- 
lene bisacrylamide (electrophoresis grade) was from 
Polysciences. Ibotenic acid was obtained from Regis 
Chemical (Morton Grove, IL). Molecular weight stan- 
dards for SDS gel electrophoresis were from Bio-Rad. 
SDS, ATP, a-chymotrypsin, ergotamine tartrate, a-ergo- 
criptine, ergonovine, 2-mercaptoethanol, phosphoserine, 
and phosphothreonine were from Sigma Chemical. All 
other chemicals were of reagent quality. 
The following were gifts, generously provided by the 
person or company indicated: bromocriptine (Sandoz 
Pharmaceuticals, East Hanover, NJ); (+)- and (-)-bu- 
taclamol (Ayerst Laboratories, New York, NY); chlor- 
promazine (Smith, Kline and French, Philadelphia, PA); 
clonidine HC1 (Boehringer Ingelheim, Ridgefield, CT); 
dihydroergocriptine (Sandoz Pharmaceuticals); fluphen- 
azine HCI (E. R. Squibb and Sons, Princeton, NJ); hal- 
operidol (Dr. R. Katz, University of Michigan); metoclo- 
pramide HCl (A. H. Robins, Richmond, VA); molindone 
(Abbott Laboratories, N. Chicago, IL): phentolamine 
mesylate (Ciba Pharmaceuticals, Summit, NJ); quipazine 
(Dr. J. Woods, University of Michigan); spiroperidol 
(Janssen Pharmaceutica, New Brunswick, NJ); sulpiride 
(Delagrange Intl . ,  Paris, France);  thioridazine HCl 
(Sandoz Pharmaceuticals); trifluoperazine dihydro- 
chloride (Smith, Kline and French); yohimbine HCI (Dr. 
C. B. Smith, University of Michigan). Purified calmod- 
ulin was the gift of Dr. M. E. Gnegy (University of Mich- 
igan), and phosphotyrosine was the gift of Dr. S. Cohen 
(Vanderbilt University). All other chemicals used were of 
reagent quality. 
Krebs-Ringer bicarbonate buffer (KRB) (Daly et al., 
1980) was prepared fresh each day and contained the fol- 
lowing components (millimolar concentrations): NaCl 
(122); NaHCO, (25); D-ghCOSe (10); KCI (3.0); KH,PO, 
(1.0); MgSO, (1.2); CaCI, (1.3). The solution was gassed 
with 95% 0,-5% CO, to pH 7.4 prior to use. 
Preparation of a synaptosome fraction 
A crude syaptosome fraction (P2) was prepared from 
rat cerebral cortex (unless otherwise indicated) using a 
method similar to that described by Daly et al. (1980). 
Rats were killed by decapitation. Brains were removed 
and cortical regions were dissected free of striatal regions 
and excess white matter. The cortices were then roughly 
chopped with a scalpel, immersed briefly in ice-cold 
KRB, drained on a small nylon mesh screen, and 
weighed. Homogenization was carried out in three vol- 
umes of KRB in a teflon-glass homogenizer (five or six 
strokes, 900 rpm). The homogenate was centrifuged at 
1,000 g,,,, IS min. The resulting supernatant was centri- 
fuged at 20,000 g,,,, 20 min. The resulting pellet (P,) was 
resuspended in three volumes of KRB (based on original 
wet weight) by gentle homogenization by hand. 
Standard assay for phosphorylation of the 
P, fraction 
Aliquots (50 pl, 60-80 pg protein) of the P, suspension 
were transferred to tubes on ice containing 35 pl KRB 
and 5 pl test agent. The mixtures were preincubated at 
37°C for 2 min in a shaking water bath. The phosphory- 
lation reaction was initiated by addition of 10 pl [y- 
3zP]ATP (40 pM, 5- I0 Ciimmol). After a 2-min incubation 
period, the reaction was terminated by addition of SO pl 
SDS stop solution containing 0.186 M Tris-HCI, pH 6.7: 
9% SDS: 15% (vol/vol) glycerol; 12% 2-mercaptoethanol; 
and a trace of bromphenol blue (Ueda and Greengard, 
1977) followed by immediate placement in a boiling water 
bath. Modifications to this procedure, when applicable, 
are indicated in the text and/or figure legends. 
Lesions of the guinea pig hippocampus 
Three unilateral infusions of 10 pg ibotenic acid, each 
in 4 pl phosphate-buffered saline (pH 7.4), were admin- 
istered to seven guinea pigs, as previously described 
(Fisher et al., 1981). The contralateral side of the hip- 
pocampus served as a control. Anodal electrolytic lesions 
were placed in the fornix-fimbria of six guinea pigs as 
described by Fisher et al. (1980) to effect bilateral abla- 
tion of this pathway. Unoperated animals served as con- 
trols for the fornix-fimbria-lesioned animals. 
Preparation and phosphorylation of guinea pig 
hippocampal homogenates 
Ibotenate-treated guinea pigs were sacrificed 13 days 
postinjection, and those with lesions of the fornix-fim- 
bria, 7-10 days postlesion. Guinea pigs were killed by 
stunning and exsanguination, followed by removal of the 
cerebrum and dissection of the hippocampal formation 
(dentate gyrus and hippocampus proper) from the sur- 
rounding tissue. Tissues were weighed and homogenized 
in three volumes KRB (five or six strokes in a Teflon- 
glass homogenizer, 900 rpm). An aliquot of this homog- 
enate was then diluted in six and one-half volumes 0.32 
M sucrose for all enzyme assays. Immediate preparation 
and use of the tissues was essential to obtain consistent 
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control phosphorylation levels between animals. Twenty 
microliters of tissue suspension were added to 75 p1 KRB 
in test tubes resting in an ice bath. Phosphorylation of 
samples in the presence of bromocriptine (25 p M ,  final 
concentration) or carrier was carried out as described for 
the P, fraction. All tissue samples were assayed in trip- 
licate. 
SDS polyacrylamide gel electrophoresis 
and autoradiography 
Phosphorylated samples ( IOO-pI aliquots) were applied 
to discontinuous SDS polyacrylamide slab gels. The com- 
position of these gels was identical to that described by 
Ueda and Greengard (1977), except that a 6.9% acryl- 
amide resolving gel was used unless otherwise indicated. 
Electrophoresis was carried out at constant voltage (40 
V,  overnight). Gels were stained, dried, and placed on X- 
ray film for autoradiography for 2-5 days. In some cases, 
Cronex intensifying screens (DuPont) were employed. 
Quantification of 32P-phosphate incorporation into pro- 
tein bands was performed as described by Ueda et al. 
(1973). Darkness of the autoradiograph was measured by 
a scanning densitometer and expressed as arbitrary units. 
The arbitrary units were converted to fmol of incorpo- 
rated 32P-phosphate by determining the radioactivity 
present in representative protein bands from the same gel 
in a liquid scintillation counter. 
Peptide mapping 
Phosphorylated samples were subjected to SDS-poly- 
acrylamide gel electrophoresis as described above. Fol- 
lowing electrophoresis, the unstained gels were soaked 
in several changes of acetic acid-methanol-water (1 :5:4), 
dried, and autoradiographed. With the autoradiograph as 
a guide, the pieces of gel containing phosphoproteins 
were excised, scraped of paper backing, and the proteins 
were eluted as described by Huttner and Greengard 
(1979). Elution was carried out at 37°C for 20 h in 50 mM 
ammonium bicarbonate- 1 mM dithiothreitol containing 75 
pglml each trypsin and chymotrypsin (1 ml/protein band) 
plus a trace of phenol red. The eluate was removed and 
fresh elution buffer added for further incubation at 37°C 
for 6 h. (Concentration of enzymes was reduced to 25 pgl 
ml during the second elution.) The eluates were pooled 
and lyophilized in a rotary evaporator (Savant). Samples 
were dissolved in 10-50 pl of high-voltage electropho- 
resis buffer composed of 10% acetic acid and 1% pyridine 
(vol/vol), pH 3.5. Samples were then spotted on cellulose 
thin-layer plates (Eastman Kodak 13255), and subjected 
to high-voltage electrophoresis (1,000 V, 30 min). The 
plates were air-dried and subjected to ascending chro- 
matography in the second dimension using a solution of 
n-butanol-p yridine-acetic acid-water (37.5 : 25 : 7.5 : 30). 
Dried thin-layer plates were placed on X-ray film for au- 
toradiography. 
Phosphoamino acid analysis 
The P, fraction was phosphorylated in the absence or 
presence of 25 p M  bromocriptine, as described above, 
except that the specific activity of [Y-~*P]ATP was in- 
creased to 20 Ci/mmol. Samples were electrophoresed at 
180 V for 18 h on 27-cm long SDS gels (6.9%). The gels 
were rinsed briefly with distilled water, immediately 
dried, and subjected to autoradiography. Those portions 
of the gel corresponding to the positions of the bromo- 
criptine-sensitive 50,000- and 60,000-dalton phosphopro- 
teins were excised, using the autoradiograph as a guide. 
The proteins were extracted from the gels with 0.1% 
SDS-0.05 M NH,CO,, precipitated with 20% trichloro- 
acetic acid, and the precipitates washed successively with 
ethanol and ethanol-ether (1:l) at - 10°C, as described 
by Beemon ad Hunter (1978). The washed precipitates 
were dissolved in 1 ml of 98% formic acid, lyophilized, 
redissolved in 1 ml of 6 M HCI, and hydrolyzed in V ~ C U O  
at 110°C for 2 h, as described by Eckhart et al. (1979). 
The samples were then lyophilized and dissolved in 60 pl 
of pH 2 electrophoresis buffer [glacial acetic acid-formic 
acid (88%)-water, 78:25:897] containing 5 mM each au- 
thentic phosphoserine, phosphothreonine, and phospho- 
tyrosine. Ten microliters of each sample were applied to 
separate thin-layer cellulose plates (Eastman Kodak 
13255) and electrophoresed toward the anode (1,000 V,  
90 min). The plates were then dried and chromatographed 
in the second dimension in  isobutyric acid-0.05 M 
NH,CO, (5 :3 ) .  Phosphoamino acid markers were de- 
tected by ninhydrin staining. Autoradiography was car- 
ried out at - 70°C, using intensifying screens. 
Marker enzyme assays 
Choline acetyltransferase (EC 2.3.1.6, ChAT) activity 
was measured in guinea pig hippocampal homogenates 
by the method of Fonnum (1975). Glutamate decarbox- 
ylase (EC 4.1.1.15, GAD) activity was measured in the 
homogenates as described previously (Fisher et al., 1980) 
with the exceptions that the final concentration of sodium 
L-glutamate was 20 mM and incubations were terminated 
after 60 min. All tissue samples were assayed in triplicate. 
Paired Student's r-tests were used to compare means of. 
data from ibotenate-treated guinea pigs, since both con- 
trol and treated tissues were taken from each animal. 
Unpaired Student's f-tests were employed for compari- 
sons between groups of animals used in the fornix-fimbria 
lesion studies. 
Protein determination 
Protein concentration was determined by the method 
of Lowry et al. (1951), with bovine serum albumin as 
standard. 
RESULTS 
Effects of neurotransmitters and agonists on 
synaptosome protein phosphorylation 
Figure 1 shows the results of an experiment in 
which a number of neurotransmitters and neuro- 
transmitter agonists were tested for effects on phos- 
phorylation of proteins in a crude synaptosome (P2) 
fraction of rat cerebral cortex. Bromocriptine (25 
p M ) ,  an ergot with dopamine-mimetic properties 
(Fuxe et a].,  1978; Kebabian and Calne, 1979), 
caused a marked inhibition of the phosphorylation 
of 50,000- and 60,000-dalton proteins, and a slight 
inhibition of the phosphorylation of a 150,000- 
dalton protein (P,,o). However, neither dopamine 
nor any of the other neurotransmitters or agonists 
tested significantly altered the phosphorylation of 
these or other proteins in the P, preparation under 
the conditions employed in this study. In other ex- 
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FIG. 1. Effects of various neurotransmitters and agonists on 
protein phosphorylation in the P, fraction of rat cortex. Ali- 
quots of the P, fraction (60 pg protein) were subjected to 
phosphorylation for 2 min in the absence (control; CON) or 
presence of 25 pM bromocriptine (BrC), dopamine (DA), nor- 
epinephrine (NE), isoproterenol (ISO), serotonin (5HT), his- 
tamine (HIS), carbachol (CAR), or GABA (GAB), as described 
in Materials and Methods. Aliquots (40 pg protein) of the 
phosphorylated samples were subjected to SDS-gel electro- 
phoresis (40 V, 16 h; followed by 100 V, 1 h) and autoradiog- 
raphy as described in Materials and Methods. BrC-P,, and 
BrC-P,,, Brornocriptine-sensitive phosphoproteins with ap- 
proximate molecular weights of 50,000 and 60,000, respec- 
tively. 200K, 200,000; 135K, 135,000; 94K, 94,000; 68K, 68,000; 
44K, 44,000. 
periments not shown here, the potent dopamine ag- 
onist apomorphine (25 p M )  caused only a slight in- 
hibition of the phosphorylation of these proteins. 
Moreover, the bromocriptine-induced inhibition 
was not prevented by any of the dopamine antag- 
onists tested (data not shown). These observations 
suggest that the inhibitory effect of bromocriptine 
is not mediated through dopamine receptors. 
The major bromocriptine-sensitive phosphopro- 
teins with molecular weights of 50,000 and 60,000 
will hereafter be referred to as BrC-P,, and BrC- 
P,,, respectively. Experiments were carried out to 
determine the nature of the bromocriptine-induced 
reduction of phosphorylation of these proteins. Ad- 
dition of bromocriptine to the reaction mixture after 
preincubation of the P, fraction with [y32P]ATP, fol- 
lowed by additional incubation, did not result in a 
change in the state of phosphorylation of these pro- 
teins as compared with control (data not shown). 
This experiment suggests that the effect of bromo- 
criptine on BrC-P,, and BrC-P,, phosphorylation 
does not reflect activation of a specific protein 
phosphatase. The possibility that bromocriptine 
causes the disappearance of these phosphoproteins 
via activation of a specific phosphoprotein protease 
was tested by subjecting the phosphorylated sam- 
ples to electrophoresis on SDS-polyacrylamide 
(15%) gels. No appearance of new lower molecular 
weight phosphoprotein species in bromocriptine- 
treated samples was observed. In addition, cyclic 
AMP had no effect on the state of phosphorylation 
of BrC-P,, and BrC-P, (data not shown). On the 
basis of these observations, we conclude that bro- 
mocriptine directly inhibits the protein phosphory- 
lation reaction. 
Time course of phosphorylation of BrC-P,, 
and BrC-P, 
To characterize further the bromocriptine-sensi- 
tive phosphorylation, the time course of net phos- 
phorylation of BrC-P,, and BrC-P, was determined 
in the presence of 4 p M  ATP, both in the absence 
and in the presence of 25 p M  bromocriptine. As 
shown in Fig. 2, maximal phosphorylation of both 
proteins occurred within 15 s after addition of ATP 
to the reaction mixture. Bromocriptine decreased 
both the rates and the final levels of net phosphor- 
ylation of BrC-P,, and BrC-P,,. When a saturating 
concentration of ATP (500 pM) was used, bromo- 
criptine had little effect on the final levels, although 
it reduced the rates of phosphorylation substantially 
(data not shown). The final levels of phosphoryla- 
tion of both proteins were approximately 25-fold 
higher under the ATP-saturating conditions than 
under standard conditions. Also apparent from 
these experiments is the relatively slow turnover of 
32P-phosphate on these phosphoproteins. Thus, 
after an incubation period of 10 min, only a slight 
decrease in their phosphorylation levels was ob- 
served (Fig. 2), indicating that the P, preparation 
contains relatively low levels of BrC-P,, and/or 
BrC-P, phosphatase. 
Effect of ATP concentration on phosphorylation 
O f  BrC-P,, and BrC-P,o 
The phosphorylation of BrC-P,, and BrC-P,? as a 
function of ATP concentration is shown in Fig. 3 .  
In this experiment, the incubation was carried out 
for 5 s in an effort to obtain initial rates. Maximal 
phosphorylation of both proteins occurred with 
ATP concentrations >50 p M .  From the Hanes plots 
of these data shown in the insets of Fig. 3 ,  apparent 
K,’s of the phosphorylation of BrC-P,, and BrC-P,, 
for ATP were determined to be 17.6 pM and 15.5 
pM, respectively. Apparent Vmax’s of the reactions 
were determined to be 131 fmol * s- l  and 122 
fmol * s-l, respectively. 
Ion requirements for phosphorylation of BrC-?,, 
and BrC-P,o 
Under standard conditions, phosphorylation of 
the P, fraction was carried out in the presence of a 
KRB solution approximating the ionic composition 
of the extracellular fluid in the brain (Dingledine et 
al., 1980). In experiments designed to determine ion 
requirements of the bromocriptine-sensitive phos- 
phorylation reaction, it was found that addition of 
EGTA to the reaction mixture caused a marked de- 
crease in the phosphorylation of both BrC-P,, and 
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FIG. 2. Time course of phosphor- 
ylation of BrC-P,, and BrC-P,,. Ali- 
quots (50 pg protein) of the P, frac- 
tion were incubated with 4 p M  ATP 
(final concentration) for various 
periods of time in the absence (0) 
or presence (0) of 25 pM bromo- 
criptine, as described in Materials 
and Methods. Aliquots (50 pg pro- 
tein) of the reaction mixture were 
subjected to SDS-gel electropho- 
resis and autoradiography. Quan- 
titation of 32P-phosphate into pro- 
tein bands was carried out as de- 
scribed in Materials and Methods. 
A: BrC-P,,. 8: BrC-P,,. 
BrC-P,, (data not shown). Therefore, calcium de- 
pendence of the reaction was investigated further. 
Figure 4 shows the effect of varying the calcium 
concentration in the presence of 3 mM EGTA on 
the phosphorylation of BrC-P,, and BrC-P,, in the 
presence of 0 mM, 1.2 mM, and I0 mM magnesium. 
From these data, it is clear that calcium markedly 
stimulates the phosphorylation of BrC-P,, and BrC- 
P60. The free calcium concentrations required for 
one-half maximal stimulation of phosphorylation, 
calculated as described by Nanninga and Kempen 
(1971), were in the range of 2-7 p.M. Figure 4 also 
demonstrates the magnesium requirement of the 
protein phosphorylation. 
Addition of purified calmodulin caused a sub- 
stantial increase in the phosphorylation of BrC-P5, 
and BrC-P,, (Table I) .  The calmodulin-stimulated 
activity was also inhibited by bromocriptine. These 
results suggest that the bromocriptine-sensitive 
phosphorylation of BrC-P,, and BrC-P,, is cata- 
lyzed by calciumkalmodulin-dependent protein ki- 
nase(s). 
1 2 0 -  ' I I I I I I I - I Z 0  - B.'BrC-b50 ' I I 1 I 1 -  - A .  0rC- p60 
- - - - 0 
W 
I- L O O -  a 
(L 80- - 0 0 -  - 
- 
0 
20 40 60 80 20 40 60 80 
ATP (AIM) ATP O M )  
FIG. 3. Effects of various concentrations of ATP on phosphorylation of BrC-P,, and BrC-P,,. Aliquots (69 pg protein) of the P, 
fraction were preincubated at 37°C for 2 min. [y-32P]ATP was added to each sample to yield the final concentrations indicated, 
and the reaction terminated after 5 s incubation time. SDS-gel electrophoresis, autoradiography, and quantitation of 32P- 
phosphate incorporated into protein bands were carried out as described in Materials and Methods. Insets show the data 
plotted as the Hanes transformation (Cornish-Bowden, 1979) of the Michaelis-Menten equation: ( S h )  = (Km/Vmax) + (S/Vmax). 
The x-intercept represents - K,(app); the y-intercept represents - K,(app)/V,,,(app), and the slope of the line equals l/V,,,(app). 
Lines drawn are from linear regression by least squares analysis of the data. A: BrC-P,,, K,(app) = 15.5 pM; V,,(app) = 122 
fmol s-l. B: BrC-P,,, K,(app) = 17.6 pM; V,,(app) = 131 fmol S-'. 
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FIG. 4. Effects of various concentrations of calcium ions on 
phosphorylation of BrC-P,, and BrC-P,,. The P, fraction was 
resuspended in calcium- and magnesium-free KRB. Aliquots 
(40 kg) were incubated with [y-32P]ATP in the presence of 3 
mM EGTA and of the final concentrations of magnesium and 
calcium indicated, as described in Materials and Methods. 
Phosphorylation of samples, autoradiography, and quanti- 
tation of 32P-phosphate incorporation into protein bands 
were carried out as described in Materials and Methods. A: 
BrC-P,,. 8: BrC-P,,. (O), 0 mM Mg2+; (0), 1.2 mM Mg2+; (O), 
10 mM Mgz+. 
Phosphoamino acid analysis of BrC-P,, 
and BrC-P,q 
To determine the 32P-phosphoamino acid residues 
in BrC-P,, and BrC-P,,, phosphorylated BrC-P,, 
and BrC-P,, were separated from other phospho- 
proteins by SDS-gel electrophoresis, eluted from 
gels, and subjected to partial acid hydrolysis. The 
hydrolysates were then analyzed for [32P]phos- 
phoserine, [32P]phosphothreonine, and [3'P]phos- 
photyrosine by electrophoresis in the first dimen- 
sion and chromatography in the second dimension. 
As shown in Fig. 5, bromocriptine-sensitive phos- 
phorylation occurs on a threonine residue(s) of both 
BrC-P,, and BrC-P,,. Although to lesser degrees, 
both of the proteins were also phosphorylated on a 
serine residue(s); however, the serine phosphory- 
lation was not affected by bromocriptine. Whether 
the phosphoserine resides in BrC-P,, and BrC-P,, 
or in contaminating proteins with similar molecular 
weights is not known at present. 
Phospho-peptide mapping of BrC-P,, and BrC-P,, 
The similarities in the phosphorylation of BrC- 
P,, and BrC-P,, noted in the experiments described 
above indicated that the proteins themselves might 
be similar. Therefore, to compare further BrC-P,, 
and BrC-P,,, the phosphoproteins were subjected 
to analysis by peptide mapping as described in Ma- 
terials and Methods. Figure 6 shows the phosphor- 
ylated peptide fragments produced after the tryptic/ 
chymotryptic digestion. It appears that BrC-P,, and 
BrC-P, share many identical or highly similar phos- 
phopeptides (labeled 1-6). Although precise quan- 
titative comparisons could not be made between 
plates due to differential recovery of samples from 
the original gel, a close examination of the changes 
in the phosphopeptide patterns indicates that bro- 
mocriptine inhibited 32P-phosphate incorporation 
into most, but not all, of the phosphopeptides. 
Bromocriptine had relatively small effects on the 
phosphorylation of the peptide fragments labeled 8 
and 9 of BrC-P,,and of the fragments labeled 10 
and 11 of BrC-P,,. It is therefore likely that these 
phosphopeptides contain phosphoserine residue( s). 
Tissue distribution of bromocriptine-sensitive 
protein phosphorylation 
Various tissue homogenates were examined for 
bromocriptine-sensitive phosphorylation of 50,000- 
and 60,000-dalton proteins. As shown in Fig. 7A 
and B, the bromocriptine-sensitive phosphorylation 
system is most highly concentrated in the brain. It 
was not detected in nonnervous tissues such as 
heart, liver, kidney, lung, and spleen. Although 
each of these tissues has a phosphoprotein whose 
electrophoretic mobility is indistinguishable from 
that of BrC-P,,, its phosphorylation is not bromo- 
criptine-sensitive. It may be noted, however, that 
adrenal tissue exhibits bromocriptine-sensitive 
phosphorylation of a 50,000-dalton protein. 
The distribution of BrC-P,! and BrC-P,, within 
some brain regions is shown in Fig. 8.  The bromo- 
criptine-sensitive BrC-P,, phosphorylation system 
is present in all of the brain regions tested; however, 
there are regional differences in their specific con- 
tents. Thus, the phosphorylation of BrC-P,, is the 
highest in the hippocampus, followed by the cortex 
and striatum, and is lowest in the hypothalamus. 
With the exception of the cerebellum, the distri- 
bution of BrC-P,, is roughly parallel to that of BrC- 
P,,. The cerebellum has a relatively much lower 
level of BrC-P,,; instead, a bromocriptine-sensitive 
56,000-dalton phosphoprotein is prominent. This 
phosphorylation system is much more abundant in 
the cerebellum than in the other regions examined. 
In the hypothalamus, the 56,000-dalton protein is 
the most prominent phosphoprotein component. 
The pituitary, which is not part of the brain proper, 
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does not appear to possess a bromocriptine-sensi- 
tive phosphorylation system. 
Cellular localization of BrC-P,, and BrC-P,, 
To investigate the cellular localization of BrC-P,, 
and BrC-P,, within the brain, we carried out lesion 
studies on the guinea pig hippocampus. In these 
studies ibotenic acid, a toxin that selectively de- 
stroys neuronal cell bodies but spares nerve ter- 
minals and axons of passage (Schwarcz et al., 1979; 
Kohler et al., 1979; Fisher et al., 1981), was injected 
into one side of the guinea pig hippocampus. Thir- 
teen days postlesion, the two sides were compared 
for bromocriptine-sensitive protein phosphorylation 
and marker enzymes as described below. In addi- 
tion, the effects of electrolytic lesions of the fornix- 
fimbria on protein phosphorylation and marker en- 
zyme activities in the hippocampus were investi- 
FIG. 5. Analysis of phospho-  
amino acid residues i n  BrC-P,, 
and BrC-P,, by electrophoresis 
and chromatography on  th in-  
layer cellulose. Al iquots of P, 
fraction prepared from rat cortex 
(150 pg protein) were subjected 
t o  phosphorylat ion in the  ab- 
sence or presence of 25 pM 
bromocriptine, in a final volume 
of 0.2 ml, as described in Mate- 
r ials and Methods. Fol lowing 
electrophoresis (180 V, 20 h) on 
27-cm long gels, the BrC-P,, and 
BrC-P,, bands were identified by 
autoradiography; the portions of 
the gels containing BrC-P,, and 
BrC-P,, were excised and ex- 
tracted from the gel wi th  O.lo/o 
SDS-0.05 M NH,CO,, followed by 
acid hydrolysis, as described in  
detail in Materials and Methods. 
The lyophilized samples were dis- 
solved in a pH 2 electrophoresis 
buffer containing 5 m M  each au- 
thent ic  phosphoserine, phos- 
phothreonine, and phosphotyro- 
sine, spotted on TLC plates, and 
analyzed by electrophoresis in  
the first dimension and by chro- 
matography in the second dimen- 
sion, as described i n  Materials 
and Methods. P-Ser, Phospho- 
serine; P-Thr, phosphothreonine; 
P-Tyr, phosphotyrosine. + ,  
anode; - ~ cathode. 
gated. In both series of experiments, hippocampal 
homogenates were used for the protein phosphor- 
ylation assays. 
Zbotenate lesions of the hippocumpus. Following 
unilateral intrahippocampal injection of ibotenate, 
the lesioned side of the hippocampus was shrunken 
in appearance and weighed 26% less than the con- 
trol side. In homogenates obtained from the le- 
sioned hippocampus, the specific activity of GAD, 
a marker for intrinsic y-aminobutyric acid (GABA)- 
ergic neurons (Storm-Mathisen, 1972), was reduced 
by 40%. However, ChAT activity was not signifi- 
cantly reduced following ibotenate treatment (Table 
2), confirming the selective toxicity of this agent. 
The concentration of proteidmg wet weight was 
also not altered by the lesion (Table 2). 
Incubation of guinea pig hippocampal homoge- 
nates in the presence of [Y-~*P]ATP resulted in the 
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TABLE 1 .  Effect of calmodulin on phosphorylation of 
BrC-P,, and BrC-P,, 
Phosphorylation 
(fmol 3ZP-phosphate) 
Control + Calmodulin 
Bromocriptine 
(PW BrC-P,, BrC-P,, BrC-P,, BrC-P,, 
0 74 63 295 359 
100 24 23 91 77 
Phosphorylation was carried out under standard conditions as 
described in Materials and Methods, except that purified cal- 
modulin (1  pg) was added to some samples prior to the addition 
of carrier or bromocriptine. Quantitation of '*P-phosphate was 
carried out as described in Materials and Methods. 40 pg of 
protein were present in each sample. 
rapid appearance of label in several phosphopro- 
teins, the most prominent being BrC-Pso and BrC- 
P,, (Fig. 9). Inclusion of bromocriptine in the assay 
resulted in a selective inhibition of the phosphory- 
lation of these two proteins by 57-69% (Table 2). 
(Differences between groups were not statistically 
significant.) Ibotenate lesion of the hippocampus re- 
sulted in a marked reduction in the basal phos- 
phorylation of BrC-P,, (55%) and BrC-P,, (51%) 
FIG. 6. Peptide mapping of BrC- 
P,, and BrC-P,,. The P, fraction 
was prepared from rat cortex and 
aliquots phosphorylated in the 
absence or presence of 25 F M  
bromocriptine. Phosphorylated 
BrC-P,, and BrC-P,, were ex- 
tracted from SDS-gels and sub- 
jected to exhaustive trypsinkhy- 
motrypsin digestion as described 
in Materials and Methods. Sam- 
ples were applied to cellulose 
thin-layer plates at small arrows, 
and phosphorylated peptides 
were separated by electropho- 
resis followed by ascending chro- 
matography in dimensions indi- 
cated in the figure, as described 
in Materials and Methods. Shown 
here are autoradiographs of thin- 
layer plates. A: Phosphopeptides 
of BrC-P,, phosphorylated in the 
absence (left) and presence 
(right) of bromocriptine. B: Phos- 
phopeptides of BrC-P,, phos- 
phorylated in the absence (left) 
and presence (right) of bromo- 
criptine. 
(Table 2). However, the percentage inhibition of 
phosphorylation resulting from addition of bromo- 
criptine to homogenates prepared from the lesioned 
side of the hippocampus was comparable to that 
obtained from the control side (Table 2). Thus, the 
structures remaining undestroyed by the neurotoxin 
retain a functional bromocriptine-sensitive protein 
phosphorylation system. 
Fornix-Jimbria les ions.  Transection of the fornix- 
fimbria resulted in a 71% reduction of ChAT ac- 
tivity, an indicator of the structural integrity of this 
pathway (Lewis et al., 1967). However, the lesion 
had no effect on hippocampal wet weight, protein 
content, or GAD activity (Table 2). Similarly, nei- 
ther the basal phosphorylation of BrC-Pso or BrC- 
P,, nor the magnitude of bromocriptine inhibition 
was affected by the lesion (Table 2; Fig. 9). 
Effects of other ergots and centrally active agents 
on BrC-P,, and BrC-P,, 
Since dopamine (Fig. 1 )  and the potent dopamine 
agonist apomorphine (data not shown) failed to 
mimic the inhibitory effect of bromocriptine on the 
protein phosphorylation, it is unlikely that the in- 
hibitory effect can be ascribed to the dopaminergic 
properties of the ergot. Structurally, bromocriptine 
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FIG. 7. Tissue specificity of bromocriptine-sensitive phosphorylation of BrC-P,, and BrC-P,,. Various tissues as indicated were 
homogenized in three volumes of KRB, and a subcellular fraction was prepared in the same manner as for the P, fraction of 
rat cortex. Aliquots of the fraction (brain, 56 pg protein; heart, 70 kg  protein; liver, 88 pg protein; kidney, 100 pg protein; 
spleen, 113 pg protein; and adrenal gland, 20 pg protein) were subjected to phosphorylation in the absence or presence of 
100 pM bromocriptine (BrC), followed by SDS-gel electrophoresis (40 V, 18 h) and autoradiography, as described in Materials 
and Methods. A (left): Comparison of brain, heart, liver, and kidney. B (right): Comparison of brain, lung, spleen, and adrenal. 
is classified in a group of ergots termed ergopep- 
tines, which contain peptide moieties substituted on 
the ergoline ring structure (Rall and Schleifer, 
1980). To determine whether the inhibitory effect of 
bromocriptine is attributable to the ergoline ring 
structure, the peptide moiety, or to both, various 
ergot compounds were tested for their capacities to 
inhibit the phosphorylation of BrC-P,, and BrC-P,. 
As shown in Fig. 10 and Table 3, those ergots that 
possess peptide moieties-a-ergocriptine, dihy- 
droergocriptine, and ergotamine-were slightly 
less potent than bromocriptine in inhibiting phos- 
phorylation of BrC-P,, and BrC-P,,. Those ergots 
that lack peptide moieties, such as methysergide 
and ergonovine, had little or no effect. The dopa- 
mine-mimetic ergot lergotrile (Kebabian and Calne, 
1979), which does not possess a peptide moiety, was 
relatively ineffective in causing the inhibition; 
bromocriptine was more than 10 times as potent as 
was lergotrile. It appears that the presence of a par- 
ticular peptide moiety in the ergots is crucial in 
causing a potent and specific inhibition of the phos- 
phorylation of BrC-P,, and BrC-P,,. Thus, although 
bromocriptine was the most potent of all agents 
tested, its potency was not greatly different from 
that of a-ergocriptine or dihydroergocriptine, both 
of which have a peptide moiety identical to that of 
bromocriptine. On the other hand, ergotamine, 
which has a different peptide moiety, was signifi- 
cantly less potent than the above ergopeptines. 
In an effort to establish the specificity of the in- 
hibitory effect of bromocriptine, a variety of other 
neuroactive agents, including dopamine antago- 
nists, a- and P-adrenergic agents, and serotonergic 
agents, were tested for their capacities to inhibit 
phosphorylation of BrC-P5, and BrC-P,,. As shown 
in Table 3 ,  none of these agents caused as potent 
an inhibition as did bromocriptine. Among all the 
nonergot agents tested, spiroperidol, a potent do- 
pamine antagonist, was the most potent inhibitor. 
However, the IC,, values are several orders of mag- 
FIG. 8. Effects of bromocriptine on phosphorylation of pro- 
teins in various regions of rat brain and pituitary. Tissues 
were pooled from three rats, P, fractions prepared, and sub- 
jected to phosphorylation as described in Materials and 
Methods. SDS-gel electrophoresis was carried out at 120 V, 
18 h, followed by 150 V, 3 h on a 27-cm long SDS-gel (6.9% 
acrylamide). BrC-P,, and BrC-P60 are indicated on left. Also 
indicated are other proteins whose phosphorylation appears 
to be affected by bromocriptine (+ ,  25 pbf) (P,50, p762 p56, 
P5J. Abbreviations and amounts of protein (pg) applied to 
gel: CTX, cortex (53); STR, striatum (106); CBL, cerebellum 
(67); HIP, hippocampus (73); PIT, pituitary (46); HYP, hypo- 
thalamus (36). Positions of molecular weight standards are 
indicated at right: 200K, 200,000; 135K, 135,000; 94K, 94,000; 
68K, 68,000; 43K, 43,000. 
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TABLE 2. Effects of ibotenate and fornix-fimbria lesions on guinea pig hippocampal 
wet weight, protein content, marker enzymes, and bromocriptine- 
sensitive protein phosphorylation 
Ibotenate Fornix-Fimbria 
(n = 7) (n = 6) 
Control Lesion Control Lesion 
A. Wet weights, protein content, 
and marker enzymes 






Bromocriptine inhibition (%) 
BrC-P,, 
Basal 
Bromocriptine inhibition (%) 
B. Protein phosphorylation 
113 i 1 84 i 6a 215 i 7e 208 ? 12 
115 ? 5 1 1 1  i 5 96 2 2 93 2 3 
1.48 ? 0.14 0.89 i 0.126 1.17 i 0.09 1.12 i 0.07 
1.26 ? 0.15 1.31 ? 0.14 0.84 ? 0.03 0.24 2 0.04d 
3.20 ? 0.35 1.45 t 0.30b 2.89 ? 0.26 2.77 i 0.43 
57 i 2 46 i 5 61 2 4 56 2 5 
2.60 t 0.15 1.28 i 0.14c 3.01 i 0.16 2.71 2 0.2 
69 ? 6 65 ? 8 66 ? 3 64 i 4 
Ibotenate was injected into one side of the hippocampus, and the hippocampus divided into control 
and lesion sides for analysis as described in Materials and Methods. Fornix-fimbria lesions were 
bilateral, and control tissue was taken from separate animals; hence, the entire hippocampal formation 
was employed in these studies. Marker enzymes, protein content, and phosphorylation of BrC-P,, 
and BrC-P, were measured as described in Materials and Methods. Values shown are means i SEM 
of six or seven experiments, as indicated (n). All tissue samples were assayed in triplicate. Paired 
Student’s t-tests were used to compare values from ibotenate-treated and control samples. Unpaired 
Student’s t-tests were used to compare values from fornix-fimbria lesion and control groups. Units 
of measurement are as follows: Protein, mg/g wet weight; GAD and ChAT, nmol/mg proteidmin; 
protein phosphorylation, pmol 32P-phosphate/mg protein/2 min. 
p < 0.05, compared with control, paired analysis. 
p < 0.01, compared with control, paired analysis. 
p < 0.005, compared with control, paired analysis. 
p < 0.001, compared with control, unpaired analysis. 
In fornix-fimbria lesion experiments, entire hippocampal formations were employed, whereas 
unilateral formations were used in ibotenate treatment experiments. 
nitude higher than the concentrations required for 
eliciting other dopamine antagonistic effects 
(Clement-Cormier et  al., 1974; Iversen, 1975; 
Seeman et al., 1976; Creese et al., 1978). Moreover, 
( + )-butaclamol, another potent dopamine antago- 
nist, was not significantly different in its capacity 
to inhibit the phosphorylation of BrC-P,, and BrC- 
P60 than was the inactive enantiomer (-)-buta- 
clamol. These results are in agreement with the no- 
tion that the inhibition of BrC-P,, and BrC-P,, 
phosphorylation is not mediated through dopamine 
receptors. 
DISCUSSION 
In the present study, we have shown that bromo- 
criptine and other ergopeptines selectively inhibit 
phosphorylation of 50,000- and 60,000-dalton pro- 
teins in a crude synaptosome fraction. These bro- 
mocriptine-sensitive phosphoproteins are highly en- 
riched in the brain, particularly in the hippocampus, 
cerebral cortex, and caudate nucleus, and are not 
detectable in nonnervous tissues. 
The results of the studies directed at character- 
izing the phosphorylation of BrC-P,, and BrC-P,, 
indicate that the reactions are very much alike. The 
time course of phosphorylation of BrC-P,, and BrC- 
P6, and the apparent Michaelis constants (K,’s) for 
ATP are similar (Figs. 2 and 3). Phosphorylation of 
both proteins requires the presence of magnesium 
and calcium ions at approximately the same optimal 
concentrations (Fig. 4). In addition, phosphoryla- 
tion of both BrC-P,, and BrC-P,, is stimulated by 
calmodulin (Table 1). The amino acid residue that 
undergoes bromocriptine-sensitive phosphorylation 
is threonine in both proteins. Peptide mapping anal- 
yses of BrC-P,, and BrC-P,, indicate that the two 
proteins are digested to several identical or very 
similar phosphopeptide fragments, suggesting a ho- 
mology between the two proteins in the primary 
structure in the vicinity of the phosphorylation 
site(s). Taken together, these observations suggest 
that the bromocriptine-sensitive phosphorylation of 
both BrC-P,, and BrC-P,, is catalyzed by a single 
Ca2 +/calmodulin-dependent protein kinase. 
Although bromocriptine has been characterized 
as a dopaminergic agonist in other systems (Keba- 
bian and Calne, 1979), dopamine and other dopa- 
minergic agonists had little or no effect on the phos- 
phorylation of BrC-P,, and BrC-P,,. Dopaminergic 
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FIG. 9. Phosphoproteins in guinea pig hippocampus: effects 
of ibotenate-induced lesion and lesion of the fornix-fimbria 
on phosphorylation of proteins in homogenates of guinea 
pig hippocampus. Lesions were made and phosphorylation 
of homogenates carried out as described in Materials and 
Methods in the absence ( - )  or presence (+)  of 25 pM bromo- 
criptine (BrC). lbotenate control and lesion samples (A) are 
from the same animal. Fornix-fimbria control and lesion sam- 
ples (B) are from two separate animals. BrC-P,, and BrC-P,, 
are indicated by arrows. 
antagonists (fluphenazine, haloperidol, sulpiride) 
did not block the bromocriptine effect (data not 
shown); in fact, some dopamine antagonists mim- 
icked the inhibitory effect of bromocriptine on BrC- 
P50 and BTC-P,~. The effects of these agents were 
not, however, stereospecific. These results, and the 
observation that the highest specific content of the 
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in the hippocampus, a region of relatively low do- 
pamine content (Scatton et al., 1980), militate 
against a dopaminergic association of the bromo- 
criptine-sensitive protein phosphorylation system. 
The central effects of ergot compounds have also 
been attributed to their actions on a-adrenergic and 
serotonergic systems (Loew et al., 1978; Rall and 
Schleifer, 1980). Agonists and antagonists of these 
systems, as well as of agonists of f3-adrenergic, 
GABAergic, cholinergic, and histaminergic re- 
ceptor systems, failed to mimic the bromocriptine- 
induced inhibition of phosphorylation of BrC-P,, 
and BrC-P,, (Fig. 1 and Table 3). These results and 
the observation that the peptide-containing ergots 
are the most potent of all the agents tested in the 
selective inhibition of the phosphorylation of BrC- 
Pso and BrC-P,, raise the possibility that the BrC- 
P50 and BrC-P,, phosphorylation systems may be 
associated with a specific receptor for ergopeptines 
or for a particular peptide identical or analogous to 
the peptide moiety of bromocriptine. Whether there 
is an endogenous substance that produces the in- 
hibitory effect of bromocriptine on the protein 
phosphorylation is an interesting question that re- 
mains to be investigated. 
In studies directed at elucidating the cellular lo- 
calization of the bromocriptine-sensitive protein ki- 
nase system, we found that transection of the 
fornix-fimbria, which carries cholinergic, seroto- 
nergic, noradrenergic, histaminergic, and dopamin- 
ergic inputs to the hippocampus (Lewis et al., 1967; 
Storm-Mathisen and Guldberg, 1974; Barbin et al., 
1976; Scatton et al., 1980), did not affect the phos- 
phorylation of BrC-P,, and BrC-P,,, indicating that 
I .. 
I 0 0Xd/  
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50  - 
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-6  - 5  -4 -3  
E R G O T  ( log  M )  
FIG. 10. Effects of various ergot derivatives on phosphorylation of BrC-P, and BrC-PGo. Aliquots of a P, fraction of rat cortex 
were phosphorylated in the presence of various concentrations of ergot derivatives as indicated on abscissa (log M). Relative 
incorporation of 32P-phosphate into BrC-P,, (A) and BrC-P,, (B) was determined by scanning densitometry of autoradiographs, 
and is expressed as '70 control (X). Data are from four separate experiments; error bars represent -c SEM. (O),  Bromocriptine; 
(A), a-ergocriptine; (m), ergotamine; (V), lergotrile; (0), ergonovine. 
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TABLE 3. IC,, values for various agents on 
phosphorylation of Brc-P,, and BrC-P,, 
IC," (FM)  

















































































Aliquots of P, fraction prepared from rat cortex were phos- 
phorylated in the presence of several concentrations of each 
agent listed using standard procedures described in Materials 
and Methods. IC,, values for each agent were determined graph- 
ically from plots of % control phosphorylation vs. log concen- 
tration agent as the concentration of the agent required to cause 
50% of the maximal inhibition produced by 200 p M  bromocrip- 
tine (see Fig. 10). BrC-P, maximal inhibition = 85% of total; 
BrC-P,, maximal inhibition = 62.5% of total. IC,, values are 
listed as micromolar (pM) concentrations. >400 signifies that 
some inhibition of phosphorylation was observed at 400 F M  test 
agent, but was <50% of maximal inhibition; ( - )  signifies that 
no effect on phosphorylation was observed at maximum con- 
centration of agent tested (400 pM). 
nerve terminals derived from these tracts do not 
contribute significantly to the phosphorylation of 
the two phosphoproteins. However, phosphoryla- 
tion of BrC-P,, and BrC-P,,. and a number of other 
hippocampal proteins was significantly reduced fol- 
lowing intrahippocampal injection of ibotenate. The 
observed effects of ibotenate on protein phosphor- 
ylation are qualitatively similar to those of Sieghart 
et al. (1980), who reported that injections of a sim- 
ilar toxin, kainic acid, into the rat striatum resulted 
in a general reduction of calcium-dependent protein 
kinase activity due to the destruction of neuronal 
cell bodies. Moreover, we have recently found that 
the bromocriptine-sensitive protein phosphoryla- 
tion system is highly enriched in a postsynaptic den- 
sity fraction prepared from rat brain according to 
the procedures described by Cohen et al. (1977) (un- 
published results). Taken together, these results 
suggest that the reduced phosphorylation of BrC- 
P,, and BrC-P,, following ibotenate treatment re- 
sults from the destruction of neuronal cell bodies in 
the hippocampus that contain the bromocriptine- 
sensitive protein phosphorylation system. A glial 
cell association of the system appears unlikely, 
since a general proliferation of glial cells is observed 
following ibotenate treatment (Fisher et al., 1981). 
Nor is it likely that a major association exists be- 
tween the bromocriptine-sensitive phosphorylation 
system and the ventral (perforant) pathway, since 
this fiber tract would be spared the effects of ibo- 
tenate (Schwarcz et al., 1979). 
Calcium- and calmodulin-stimulated protein 
phosphorylation in brain tissues has been described 
by a number of investigators (DeLorenzo, 1976; 
Schulman and Greengard, 1978; Grab et al., 1981; 
Kennedy et al., 1983). In the course of our studies, 
we attempted to compare the bromocriptine-sensi- 
tive 50,000- and 60,000-dalton phosphoproteins 
with the calcium-dependent phosphoproteins of 
similar electrophoretic mobilities described by 
these authors. We found that BrC-P,, and BrC-P,, 
comigrated on one-dimensional SDS gels with the 
51,000- and 62,000-dalton Ca*+/calmodulin-stimu- 
lated phosphoproteins in crude synaptosomal prep- 
arations reported by Schulman and Greengard 
(1978) and with those in isolated postsynaptic den- 
sities reported by Grab et al. (1981). Bromocriptine 
also inhibited phosphorylation of the proteins in 
these preparations (data not shown). Recently, 
these phosphoproteins have been shown to copurify 
with calcium-dependent synapsin I kinase activity 
(Kennedy et al., 1983). We also prepared a brain 
homogenate according to the procedure described 
by DeLorenzo and coworkers (1977) and tested the 
effects of bromocriptine on phosphorylation of pro- 
teins in this fraction. We found that BrC-P,, and 
BI-C-P,~ comigrated with prominent phosphopro- 
teins termed DPH-M and DPH-L in the DeLorenzo 
preparation; however, phosphorylation of these 
proteins was only slightly inhibited by the presence 
of bromocriptine (100 pM) in the phosphorylation 
assay carried out as described by DeLorenzo et al. 
(1977). Under the conditions of our standard phos- 
phorylation assay, bromocriptine exhibited no ef- 
fect on the phosphorylation of DPH-L or DPH-M. 
DPH (400 pM), which inhibits phosphorylation of 
DPH-L and DPH-M, caused only a slight inhibition 
of phosphorylation of BrC-P,, and BrC-P,, (unpub- 
lished observations). Moreover, DPH-L and DPH- 
M have been reported to be phosphorylated mainly 
on serine residues (69-75%), with the remainder 
occurring on threonine residues (DeLorenzo et al., 
1977). Interestingly, BrC-P,, and BrC-P,, exhibited 
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almost exactly the opposite proportions. That is, 
phosphorylation was predominantly on threonine 
residues (approximately 75%), with the remainder 
on serine residues. However, only the threonine 
phosphorylation was bromocriptine-sensitive (Fig. 
5) .  Burke and DeLorenzo (1981) have reported that 
the 50,000- and 60,000-dalton phosphoprotein re- 
gions are comprised of a number of phosphopro- 
teins, including a- and P-tubulin and their kinases. 
We compared BrC-P,, and BrC-P,, with purified 
tubulin and found that they did not comigrate on 
one-dimensional SDS gels (unpublished observa- 
tions). Kennedy and coworkers (1983) reported that 
tubulin is distinct from the components of the syn- 
apsin I kinase system. Thus we conclude that al- 
though BrC-P,, and BrC-P,, have molecular weights 
in SDS in the same range as DPH-L and DPH-M 
described by DeLorenzo and coworkers, they are 
not identical to the DPH-sensitive phosphoproteins. 
However, it is possible that these phosphoproteins 
may account for some of the bromocriptine-insen- 
sitive phosphoserine residues present in our prep- 
arations. 
The functional significance of the state of phos- 
phorylation of BrC-P,, and BrC-P,, is not at present 
known. Bromocriptine, like other neurotransmitter- 
related agents, is believed to elicit pharmacological 
effects by acting on a receptor on the cell surface 
(Kebabian and Calne, 1979). Compatible with this 
notion is recent evidence, obtained using brain 
slices and neuronal cell cultures, which suggests 
that bromocriptine-sensitive phosphorylation of 
BrC-P,,.and BrC-P,, may occur on the cell exterior 
(unpublished observations). Since there is good ev- 
idence that ATP is released from nerve terminals in 
response to membrane depolarization (McIlwain, 
1972; Kuroda and McIlwain, 1974; White, 1977; 
Burnstock, 1981), it is conceivable that BrC-P!, and 
BrC-P,, phosphorylation is involved in mediating 
certain of the synaptic effects of released ATP, 
which are yet to be defined. 
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